Jetstream backs two vascular diagnostics startups in healthtech push
What's the deal? Jetstream Venture FundDealroom has a profile for this one. Try Dealroom → has invested in healthtech startups ImageAiDDealroom has a profile for this one. Try Dealroom → and Moonrise MedicalDealroom has a profile for this one. Try Dealroom →, the Scottsdale-based firm announced on August 27, 2026. Both companies build AI-enabled vascular diagnostic platforms aimed at detecting and managing Peripheral Artery Disease (PAD).
What's the endgame? ImageAiD pairs a handheld Doppler device with predictive AI software and Mayo ClinicDealroom has a profile for this one. Try Dealroom →-validated research to flag PAD in primary care years before symptoms appear. Moonrise Medical automates Doppler ultrasound assessments and Pedal Acceleration Time calculations, letting front-line clinicians evaluate vascular health without specialised sonographers.
Why now? PAD affects more than 200 million people globally and 12 million in the US. Both bets follow Jetstream's thesis of using software and automation to move diagnostics into everyday clinical settings.
How it works: Jetstream is an interval fund managed by Xcellerant VenturesDealroom has a profile for this one. Try Dealroom → and Sweater Industries LLCDealroom has a profile for this one. Try Dealroom →. It runs a $5,000 minimum initial investment and charges no carried interest, alongside positions in SpaceXDealroom has a profile for this one. Try Dealroom →, Shield AI, and Hill Research.
"Vascular care today is far too reactive; patients are routinely diagnosed only after irreversible tissue damage has occurred," said Mike Shufeldt, portfolio manager at Jetstream.
The signal: The deals show retail-accessible funds pushing into specialised medical startups typically reserved for institutional venture networks, betting that AI diagnostics can shift complex care upstream to the point of care.
Image credit: Generated with Gemini
